|Bid||266.88 x 1200|
|Ask||266.90 x 800|
|Day's Range||266.47 - 269.94|
|52 Week Range||212.50 - 287.94|
|Beta (3Y Monthly)||1.06|
|PE Ratio (TTM)||21.90|
|Earnings Date||Apr 15, 2019 - Apr 22, 2019|
|Forward Dividend & Yield||3.60 (1.33%)|
|1y Target Est||306.39|
Wall Street's Dow darlings. With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Karen Finerman, Dan Nathan and Guy Adami.
The "Halftime Report" traders take viewer questions on UnitedHealth, General Dynamics, Boeing, and Texas Instruments.
Community Health's (CYH) Q4 results disappoint with loss from decline in admissions, partially offset by lower expenses.
Until recently, the health insurance giant was restricted from operating as an HMO in its home state.
UnitedHealth Group (UNH) closed the most recent trading day at $269.51, moving -0.33% from the previous trading session.
Baltimore-based T. Rowe Price's funds, and the stock market overall, were hit hard by the stock market's dramatic plunge in December.
The usually business friendly Trump administration is not as amicably positioned for pharmacy benefit managers (PBMs) like CVS Health Corp. The pressure on PBM specifically could intensify if proposals from the Department of Health and Human Services (HHS) are enacted. According to the department's "American Patients First" proposal, released shortly after the State of the Union address earlier this month, it argues for a new "safe harbor" for prescription drug discounts offered directly to patients, as well as fixed fee service arrangements between drug manufacturers and PBMs would be created.
UnitedHealthcare announced that it will increasingly leverage data from digital devices flowing into the UnitedHealthcare Nerve Center to help people enrolled in its Medicare Advantage plans more effectively manage chronic conditions.
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! Based on UnitedHealth Group Incorporated's (NYSE:UNH) earnings update on 31Read More...
Citing a lack of patients and physician staff due to new hospital facilities in the Metro East, a surgical organization has asked the state of Illinois for permission to change ownership of one closed location and sell what remains at another shuttered facility.
Riding high on solid fourth-quarter results, a robust bottom line and strategic plans, Centene (CNC) has immense potential to reap benefits for yield-seeking investors.
UnitedHealth (UNH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
UnitedHealthcare Vision plans tied for highest in customer satisfaction among the nation’s vision carriers, according to the J.D. Power 2018 Vision Plan Satisfaction ReportSM. This
Banking on higher net income and a solid 2018 performance, Molina Healthcare (MOH) holds potential as a promising investment option.
The case for insurer UnitedHealth Group (NYSE:UNH) seems almost too easy to make. UNH stock already has been one of the best performers in the market, rising 270% over the past five years. Earnings are expected to grow about 13% in 2019. Yet UnitedHealth stock trades at a seemingly attractive 18x multiple to this year's EPS guidance.With a 10% pullback from early December highs, a cheaper price seems to set up an attractive opportunity. UNH's recent performance and huge earnings growth speak well of management. The company's Optum unit is cutting-edge, and growing revenue while expanding margins. With $226 billion in revenue, meanwhile, UnitedHealth has the scale to serve customers and the size to pressure suppliers.All else equal, I'd expect UnitedHealth stock to keep climbing. Indeed, I recommended UNH a year ago, and even ~15% higher, I'm still bullish. But there are risks here, highlighted by near-term trading in UnitedHealth stock. And investors need to understand those risks before proceeding.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 9 U.S. Stocks That Are Coming to Life Again The Case for UnitedHealth StockThis simply seems like a good business. Growth has been phenomenal. The midpoint of 2019 EPS guidance of $14.40-$14.70 suggests a 155% increase from 2014 levels.Obviously, a lower tax rate and acquisitions have provided some outside help. But this is a company operating well, with revenue and margins both rising.UNH has a diversified portfolio, too. It has its hands in seemingly every market, with the insurer serving employers, individuals, Medicare, and state and local governments. The Global segment, built through targeted M&A, is now a $10 billion-plus revenue business.And Optum is at the forefront of changes in the industry. 2018 revenue rose double-digits, and operating margins continued to expand. Other PBMs (pharmacy benefit managers) are struggling. Rite Aid (NYSE:RAD) unit EnvisionRx has disappointed. Express Scripts managed to sell itself to Cigna (NYSE:CI), but at only a modest premium to 2015 highs. In that context, Optum's performance is even more impressive.This seems simply like a very attractive business. It's the largest health insurer in the world. Optum remains a roaring success. And yet UNH stock isn't that expensive, trading at less than 18x the midpoint of FY19 EPS guidance.Double-digit annual EPS growth, a 1.4% dividend and potentially a higher multiple over time mean UnitedHealth could return 10%+ annually for years to come. The Two Key Risks to UNH StockThere are two key risks, however. The first is that competitors are trying to gain scale themselves and expand their reach. Cigna bought out Express Scripts. CVS (NYSE:CVS) acquired Aetna. Rivals are coming after UnitedHealth's market lead.To be fair, larger mergers haven't played out. Cigna and Anthem (NYSE:ANTM) planned to merge back in 2017, but called it off. Aetna and Humana (NYSE:HUM) did the same. But competitors are trying to copy at least some of UnitedHealth's strategy, and their success could make them more formidable foes.The bigger risk is on the political front. UNH stock has struggled in recent sessions after the Trump Administration announced a plan to end drug rebates (which benefit PBMs like Optum). An apparently ham-handed response from Optum, which asked for 21 month's notice of any changes from drug manufacturers, brought some unwanted publicity, and framed Optum as potentially part of the problem - not the solution.From a long term standpoint, UnitedHealth almost certainly can adapt to any changes. But with net margins only just above 5%, even modest pressure on pricing, reimbursements, or other areas of the business can have a big impact on overall profits. And in the short-term, noise around regulatory changes could impact UnitedHealth stock, as appears to have been the case of late. A Matter of TrustAt these levels, at least some of the risks are priced in. And I'd be loath to put too much faith in the federal government, in particular, doing anything to notably change the healthcare model in the U.S.But that could change. A scenario where a Democratic candidate wins the Presidency in 2020 and is backed by a Democratic Congress is far from impossible. Should such a scenario seem plausible next year, UNH stock could start pricing in that risk.Right now, 18x earnings might seem cheap but it's not hard to picture UNH trading at 13-14x (or even worse) if investors believe regulators are coming for the company's margins.The changing political landscape and UnitedHealth's exposure to that landscape, mean this isn't a set-it-and-forget-it stock. Investors need to understand the risks and be willing to be nimble if political risk, in particular, starts to creep up.In the meantime, however, the pullback in UNH stock makes an attractive business available at an enviable price. And that's enough to make UNH a buy - at least for now.As of this writing, Vince Martin has no positions in any securities mentioned. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The 7 Best Video Game Stocks to Power Up Your Portfolio! * 7 Forever Stocks to Buy for Long-Term Gains * 5 Self-Driving Car Stocks to Buy Compare Brokers The post UnitedHealth Stock Is a Buy, but Keep an Eye on the External Risks appeared first on InvestorPlace.
Dr. John Noseworthy, who just stepped down as CEO of Mayo Clinic, is keeping a presence in the health care field as he joins the board of directors of the Minnetonka-based health care giant.
The board of directors of UnitedHealth Group (UNH) announced John H. Noseworthy, M.D., has joined the board. Stephen J. Hemsley, executive chairman of the board of directors of UnitedHealth Group, said: “John Noseworthy has served health care as an exceptionally talented and compassionate physician, a leading neurological researcher and educator, and as CEO of one of the most widely recognized and admired health systems in the United States and worldwide, Mayo Clinic.
UnitedHealth Group Inc is a diversified health care company in the United States. The dividend yield of UnitedHealth Group Inc stocks is 1.31%. UnitedHealth Group Inc had annual average EBITDA growth of 13.70% over the past ten years.
The Dow Jones Industrial Average pivoted lower Monday monrng, after opening with modest gains, as shares of Walt Disney Co. and UnitedHealth Group Inc. pressured the blue-chip gauge lower. The Dow most recently was down by about 28 points, or 0.1%, at 25,075, with shares of UnitedHealth and Disney contributing about 30 points, or nearly all of the gauge's declines. Meanwhile, the other major indexes were trimming their earlier advance, with the S&P 500 index trading flat at 2,708 and the Nasdaq Composite Index holding on to a gain of about 0.2% at 7,308. All three major U.S. stock benchmarks had opened with firmer gains on Monday.
Sellers were back in the stock market Friday after the Nasdaq composite and S&P 500 suffered distribution days Thursday. In the Dow Jones today, Merck rose.